News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteonomix, Inc. (PROT) Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial With UMK-121 in End-Stage Liver Disease


9/12/2012 10:10:01 AM

PARAMUS, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-sponsored Phase 1 clinical trial with its patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). Numoda is leading provider of clinical trial information and logistics services to life sciences companies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES